Onesource Specialty Pharma share price
NSE: ONESOURCEBSE: 544292Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,377.80.
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹15,299 Cr373rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 May 2026
- 2.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 24 Jul 2026
- −0.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹11 crore of one-off items, the largest of them in the quarter to Dec 2025.
- −0.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 24 Jul 2026
- 0.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 May 2026
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,06,52963.5% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 24 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹449 Crup 4.86%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹25 Crup 443.77%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 5.6%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
| ₹ crore | Sep 2024Filed 24 Jan | Dec 2024Filed 29 Jan | Mar 2025Filed 10 Jun | Jun 2025Filed 4 Aug | Sep 2025Filed 11 Nov | Dec 2025Filed 23 Jan | Mar 2026Filed 13 May | Jun 2026Filed 24 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 68 | 393 | 426 | 327 | 376 | 290 | 428 | 449 |
| Net profit | −39 | −69 | 98 | 0 | 10 | −89 | 5 | 25 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −57.8% | −17.5% | 23.1% | −0.1% | 2.8% | −30.6% | 1.1% | 5.6% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharma, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
At or below today's level on 13% of 247 trading days over the last year.
At or below today's level on 44% of 247 trading days over the last year.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −15.9% | – | – | 0.0% |
Mutual funds holding it
93 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 46 of the 53 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 5
- AddedAdded. Funds that held more shares than at the end of the month before.
- 21
- CutCut. Funds that held fewer shares than at the end of the month before.
- 32
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 35
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal Large and Midcap FundMotilal Oswal Mutual Fund | 37,21,818 | 2.86% | ₹566.3 Cr |
| Motilal Oswal Flexi cap FundMotilal Oswal Mutual Fund | 23,91,230 | 2.71% | ₹363.8 Cr |
| Motilal Oswal ELSS Tax Saver FundMotilal Oswal Mutual Fund | 10,90,000 | 3.39% | ₹165.9 Cr |
 360 One Focused Fund360 One Mutual Fund | 10,57,754 | 2.48% | ₹160.9 Cr |
 Axis Small Cap FundAxis Mutual Fund | 9,16,559 | 0.45% | ₹139.5 Cr |
 Mirae Asset Healthcare FundMirae Asset Mutual Fund | 6,91,867 | 3.01% | ₹105.3 Cr |
| Axis Flexi Cap FundAxis Mutual Fund | 6,01,287 | 0.69% | ₹91.5 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 5,46,302 | 0.23% | ₹83.1 Cr |
| Motilal Oswal Small Cap FundMotilal Oswal Mutual Fund | 5,03,076 | 0.92% | ₹76.5 Cr |
 Aditya Birla Sun Life Flexi Cap FundAditya Birla Sun Life Mutual Fund | 4,85,952 | 0.26% | ₹73.9 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Onesource Specialty Pharma in market cap.
Onesource Specialty Pharma is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Caplin Point LaboratoriesCAPLIPOINT | 16,890 | 25.4 | 4.7 | 20.4 | +15.0% | +17.7% | 20.7% | 19.8% | 0.36% |
 PfizerPFIZER | 16,525 | 22.5 | 3.9 | 14.2 | +10.7% | −9.1% | 17.5% | 21.0% | 2.08% |
 Natco PharmaNATCOPHARM | 15,534 | 13.6 | – | – | −20.7% | −32.6% | 13.6% | 8.6% | 0.57% |
 Alivus Life SciencesALIVUS | 15,354 | 25.5 | 4.6 | 18.3 | +7.9% | +21.7% | 19.6% | 22.7% | 0.40% |
 Eris LifesciencesERIS | 15,199 | 23.6 | 3.9 | 15.3 | +9.7% | +66.4% | 19.1% | 13.8% | 0.66% |
 AstraZeneca Pharma IndiaASTRAZEN | 14,971 | 88.3 | 17.2 | 63.2 | +31.1% | −7.5% | 20.6% | 24.4% | 0.60% |
 Jubilant PharmovaJUBLPHARMA | 14,945 | 42.4 | 2.1 | 13.9 | +16.3% | −23.5% | 5.3% | 7.3% | 0.53% |
 Alembic PharmaceuticalsAPLLTD | 14,941 | 21.6 | 2.6 | 13.8 | +14.1% | +14.6% | 12.7% | 11.8% | 1.58% |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
25 Sep · Updates
23 Sep · Management
Onesource Specialty Pharma share price by year
Each calendar year to 2025.Onesource Specialty Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,810.60 | – | 2,197.80 | 1,238.20 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,377.80 | 1,377.80 | 1,320.60 | 1,334.10 | 1,341.28 | 2,06,529 | 63.5% |
| 22 Oct 2026 | 1,358.00 | 1,385.30 | 1,326.30 | 1,377.80 | 1,360.03 | 1,08,051 | 41.8% |
| 21 Oct 2026 | 1,365.70 | 1,385.00 | 1,331.30 | 1,357.10 | 1,364.20 | 2,16,713 | 63.1% |
| 19 Oct 2026 | 1,412.90 | 1,413.30 | 1,352.30 | 1,366.60 | 1,382.15 | 92,387 | 44.7% |
| 16 Oct 2026 | 1,448.40 | 1,448.40 | 1,401.90 | 1,407.80 | 1,418.26 | 1,03,563 | 45.2% |
| 15 Oct 2026 | 1,440.00 | 1,442.00 | 1,421.10 | 1,433.20 | 1,430.98 | 85,979 | 42.4% |
| 14 Oct 2026 | 1,459.10 | 1,460.00 | 1,423.90 | 1,442.40 | 1,442.17 | 3,03,380 | 64.5% |
| 13 Oct 2026 | 1,469.00 | 1,478.10 | 1,435.00 | 1,459.10 | 1,450.68 | 2,28,818 | 41.8% |
| 12 Oct 2026 | 1,461.30 | 1,503.90 | 1,442.80 | 1,471.00 | 1,475.27 | 1,67,234 | 49.9% |
| 9 Oct 2026 | 1,479.00 | 1,491.10 | 1,438.20 | 1,461.30 | 1,459.96 | 1,94,585 | 48.3% |
About Onesource Specialty Pharma
OneSource Specialty Pharma Limited is a contract development and manufacturing organisation (CDMO) for the pharmaceutical industry. It provides end-to-end development and manufacturing services to pharmaceutical and bio-pharmaceutical companies, emerging biotech firms and dedicated research and development organisations in global markets. It was incorporated in 2007. Its registered office is in Navi Mumbai and its corporate office is in Bengaluru.
The business is organised around four platforms: biologics, drug-device combinations, sterile injectables and oral technologies, which include soft gelatin capsules. The biologics platform covers microbial and mammalian expression systems, and supports programmes from gene to IND through clinical development to commercial manufacturing. The drug-device combination platform brings together formulation development, device selection, fill-finish, assembly, packaging and regulatory support. The sterile injectables platform includes lyophilised products, and the oral technologies platform offers softgel development and manufacturing.
The company operates through five facilities approved by global regulators including the USFDA, EMA, Health Canada, MHRA and WHO. One facility is a penicillin manufacturing site operated under USFDA approval. A manufacturing unit stands at Doddaballapura, Bengaluru. Its quality systems are supported by layered audits, digital quality management and continuous improvement programmes, and its environmental management system is ISO 14001:2015 certified.
Its present form comes from a Scheme of Arrangement that combined the softgel business of Strides, the Steriscience injectables business and Stelis Biopharma into the company. It is listed on the National Stock Exchange and BSE. Its chairperson, Arun Kumar, founded Strides Pharma in 1990.
- Legal name
- Onesource Specialty Pharma Limited
- NSE symbol
- ONESOURCE
- BSE code
- 544292
- ISIN
- INE013P01021
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jan 2025
- Face value
- ₹1
- CIN
- L74140MH2007PLC432497
- Corporate identity number, the registrar of companies' code for it